News

GEN - Genetic Engineering and Biotechnology News8h
StockWatch: Second Time’s the Charm for Abeona’s Gene Therapy
Zevaskyn won FDA approval upon Abeona’s second filing of a biologics license application (BLA) for the therapy.
Q&A: Two decades of research lead to treatment for rare, painful skin condition
Patients with severe dystrophic epidermolysis bullosa, or EB, have skin so fragile, the slightest touch can lead to ...
Earth.com1d
Teen skin bacteria could hold the secret to acne prevention
Scientists from MIT have discovered that the teenage years are the key window when acne-linked bacteria take hold on our ...
Dermatology Advisor2d
Zevaskyn Approved for Recessive Dystrophic Epidermolysis Bullosa
The FDA has approved Zevaskyn (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder.
Contract Pharma4d
Abeona’s ZEVASKYN Gets FDA Nod for Rare Skin Disease
The U.S. Food and Drug Administration (FDA) has approved Abeona Therapeutics Inc.’s ZEVASKYN gene-modified cellular sheets.
FDA approves Zevaskyn for rare, genetic skin disorder
The U.S. Food and Drug Administration has approved Abeona Therapeutics' Zevaskyn (prademagene zamikeracel) for patients with ...
Pharmaceutical Technology on MSN4d
FDA approves Abeona’s $3.1m cell therapy for rare skin disease
Abeona has won FDA approval for Zevaskyn, setting up a commercial challenge to Krystal Biotech in the rare skin disease ...
Health and Me on MSN4d
FDA Greenlights Zevaskyn for Rare Genetic Skin Condition
With FDA approval, Zevaskyn is set to be a game-changer in the treatment of recessive dystrophic epidermolysis ...
MedPage Today5d
FDA OKs New Gene Therapy for Debilitating Skin Condition
Patients with the debilitating dermatologic condition are born with COL7A1 mutations in both gene copies, affecting the ...
BioWorld5d
Abeona’s rare skin disease gene therapy approved by FDA
Barely a year after the U.S. FDA shackled Abeona Therapeutics Inc.’s cell-based gene therapy with a complete response letter, the agency has approved it for treating a rare and genetic skin disease.
Medscape5d
FDA Approves First One-Time Topical Treatment for Recessive Dystrophic Epidermolysis Bullosa Wounds
In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...
Crain's Cleveland Business5d
Cleveland company receives FDA approval for rare disease treatment
Cleveland-based Abeona Therapeutics Inc. (Nasdaq: ABEO) announced Tuesday, April 29, that it has received U.S. Food and Drug ...